US00974H1041 - Common Stock
AKYA stock results show that Akoya Biosciences beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Akoya Biosciences (NASDAQ:AKYA) just reported results for the fourth quarter of...
Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 millionGuiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE...
MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
PhenoCycler®-Fusion system selected as the Centre’s platform technology for advanced spatial biology studies
PhenoCycler®-Fusion system selected as the Centre’s platform technology for advanced spatial biology studies...
Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya’s spatial biology solutions
Several medtech companies are expected to release financial updates this coming week when the huge annual JP Morgan Healthcare Conference convenes in SF. Read more here here.
The Thermo Fisher Scientific ViewRNA technology combined with Akoya’s market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers
MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities ...
MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
The Thermo Fisher Scientific ViewRNA technology combined with Akoya’s market leading spatial biology solutions will enable rapid, whole-slide imaging of...
MARLBOROUGH, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
Q3 2023 revenue $25.2 million, 34% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass., Nov. 08, 2023 (GLOBE...
Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale Global network of CROs providing Akoya’s...
MARLBOROUGH, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
MARLBOROUGH, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
PhenoCycler-Fusion 2.0 enhancements enable the highest throughput workflow for spatial discovery studies.PhenoImager HT 2.0 delivers a 5x greater speed...